Jefferies Financial Group Inc. Acquires Shares of 134,500 InMode Ltd. (NASDAQ:INMD)

Jefferies Financial Group Inc. acquired a new position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 134,500 shares of the healthcare company's stock, valued at approximately $2,246,000. Jefferies Financial Group Inc. owned about 0.19% of InMode at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the stock. Raymond James Financial Inc. acquired a new position in InMode in the 4th quarter valued at $1,332,000. Barclays PLC raised its holdings in InMode by 113.5% in the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company's stock valued at $2,876,000 after acquiring an additional 90,173 shares during the last quarter. Atlas Legacy Advisors LLC acquired a new position in InMode in the 4th quarter valued at $848,000. Townsquare Capital LLC raised its holdings in InMode by 43.2% in the 4th quarter. Townsquare Capital LLC now owns 17,029 shares of the healthcare company's stock valued at $284,000 after acquiring an additional 5,137 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in InMode by 17.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 21,208 shares of the healthcare company's stock valued at $354,000 after acquiring an additional 3,193 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a report on Monday, April 28th. Barclays dropped their price objective on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a report on Wednesday, April 30th. Jefferies Financial Group dropped their price objective on InMode from $16.00 to $15.00 and set a "hold" rating for the company in a report on Monday, April 14th. BTIG Research downgraded InMode from a "buy" rating to a "neutral" rating in a report on Tuesday, April 29th. Finally, Canaccord Genuity Group dropped their price objective on InMode from $17.00 to $15.00 and set a "hold" rating for the company in a report on Tuesday, April 29th. Seven analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $18.54.

InMode Stock Down 0.3%

Shares of INMD stock traded down $0.04 on Friday, reaching $14.67. 1,037,669 shares of the stock were exchanged, compared to its average volume of 1,188,011. The stock has a market cap of $1.02 billion, a P/E ratio of 6.24 and a beta of 2.02. The firm has a 50 day moving average of $16.00 and a two-hundred day moving average of $17.34. InMode Ltd. has a 1-year low of $13.68 and a 1-year high of $19.85.

InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The company had revenue of $77.87 million during the quarter, compared to analyst estimates of $82.21 million. During the same quarter in the prior year, the company posted $0.32 earnings per share. The firm's revenue for the quarter was down 3.0% on a year-over-year basis. On average, equities research analysts predict that InMode Ltd. will post 1.75 EPS for the current fiscal year.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.